Go Pro
→ Elon Warns 'America Will Go Bankrupt'. Trump's Plan Inside. (From American Hartford Gold) (Ad)tc pixel Free OPTI Stock Alerts

OptiBiotix Health (OPTI) Competitors

OptiBiotix Health logo
GBX 5.82 -0.03 (-0.43%)
As of 12:10 PM Eastern
Compare

OPTI vs. PXS, MXC, RGT, CEL, and IDP

Should you buy OptiBiotix Health stock or one of its competitors? OptiBiotix Health's main competitors and comparable companies include Provexis (PXS), Argent BioPharma (MXC), Argent BioPharma (RGT), Celadon Pharmaceuticals (CEL), and InnovaDerma (IDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does OptiBiotix Health compare to Provexis?

OptiBiotix Health (LON:OPTI) and Provexis (LON:PXS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

OptiBiotix Health has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market. Comparatively, Provexis has a beta of 0.662, suggesting that its share price is 34% less volatile than the broader market.

0.4% of OptiBiotix Health shares are owned by institutional investors. Comparatively, 7.9% of Provexis shares are owned by institutional investors. 26.8% of OptiBiotix Health shares are owned by company insiders. Comparatively, 11.8% of Provexis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Provexis had 3 more articles in the media than OptiBiotix Health. MarketBeat recorded 3 mentions for Provexis and 0 mentions for OptiBiotix Health. OptiBiotix Health's average media sentiment score of 0.00 beat Provexis' score of -0.47 indicating that OptiBiotix Health is being referred to more favorably in the media.

Company Overall Sentiment
OptiBiotix Health Neutral
Provexis Neutral

Provexis has a net margin of -69.30% compared to OptiBiotix Health's net margin of -332.69%. Provexis' return on equity of -49.45% beat OptiBiotix Health's return on equity.

Company Net Margins Return on Equity Return on Assets
OptiBiotix Health-332.69% -77.85% -13.93%
Provexis -69.30%-49.45%-56.14%

Provexis has lower revenue, but higher earnings than OptiBiotix Health. Provexis is trading at a lower price-to-earnings ratio than OptiBiotix Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptiBiotix Health£1.29M4.73-£3.09M-£3.84N/A
Provexis£871.27K26.23-£619.15K-£0.02N/A

Summary

Provexis beats OptiBiotix Health on 7 of the 13 factors compared between the two stocks.

How does OptiBiotix Health compare to Argent BioPharma?

Argent BioPharma (LON:MXC) and OptiBiotix Health (LON:OPTI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Argent BioPharma has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, OptiBiotix Health has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market.

OptiBiotix Health has lower revenue, but higher earnings than Argent BioPharma. OptiBiotix Health is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Argent BioPharma£1.32M0.00-£17.02M-£1.66N/A
OptiBiotix Health£1.29M4.73-£3.09M-£3.84N/A

Argent BioPharma has a net margin of 0.00% compared to OptiBiotix Health's net margin of -332.69%. Argent BioPharma's return on equity of 0.00% beat OptiBiotix Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Argent BioPharmaN/A N/A -58.96%
OptiBiotix Health -332.69%-77.85%-13.93%

1.2% of Argent BioPharma shares are held by institutional investors. Comparatively, 0.4% of OptiBiotix Health shares are held by institutional investors. 8.2% of Argent BioPharma shares are held by company insiders. Comparatively, 26.8% of OptiBiotix Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Argent BioPharma's average media sentiment score of 0.00 equaled OptiBiotix Health'saverage media sentiment score.

Company Overall Sentiment
Argent BioPharma Neutral
OptiBiotix Health Neutral

Summary

Argent BioPharma and OptiBiotix Health tied by winning 5 of the 10 factors compared between the two stocks.

How does OptiBiotix Health compare to Argent BioPharma?

OptiBiotix Health (LON:OPTI) and Argent BioPharma (LON:RGT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

OptiBiotix Health has higher revenue and earnings than Argent BioPharma. OptiBiotix Health is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptiBiotix Health£1.29M4.73-£3.09M-£3.84N/A
Argent BioPharmaN/AN/A-£17.53M-£0.24N/A

OptiBiotix Health has a net margin of -332.69% compared to Argent BioPharma's net margin of -1,967.38%. Argent BioPharma's return on equity of 279.26% beat OptiBiotix Health's return on equity.

Company Net Margins Return on Equity Return on Assets
OptiBiotix Health-332.69% -77.85% -13.93%
Argent BioPharma -1,967.38%279.26%-108.57%

OptiBiotix Health has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Argent BioPharma has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

In the previous week, OptiBiotix Health's average media sentiment score of 0.00 equaled Argent BioPharma'saverage media sentiment score.

Company Overall Sentiment
OptiBiotix Health Neutral
Argent BioPharma Neutral

0.4% of OptiBiotix Health shares are held by institutional investors. Comparatively, 1.1% of Argent BioPharma shares are held by institutional investors. 26.8% of OptiBiotix Health shares are held by company insiders. Comparatively, 17.8% of Argent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

OptiBiotix Health beats Argent BioPharma on 6 of the 10 factors compared between the two stocks.

How does OptiBiotix Health compare to Celadon Pharmaceuticals?

Celadon Pharmaceuticals (LON:CEL) and OptiBiotix Health (LON:OPTI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Celadon Pharmaceuticals' average media sentiment score of 0.00 equaled OptiBiotix Health'saverage media sentiment score.

Company Overall Sentiment
Celadon Pharmaceuticals Neutral
OptiBiotix Health Neutral

OptiBiotix Health has higher revenue and earnings than Celadon Pharmaceuticals. Celadon Pharmaceuticals is trading at a lower price-to-earnings ratio than OptiBiotix Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celadon Pharmaceuticals£123.38K66.61-£4.97M-£7.98N/A
OptiBiotix Health£1.29M4.73-£3.09M-£3.84N/A

Celadon Pharmaceuticals has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market. Comparatively, OptiBiotix Health has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market.

10.7% of Celadon Pharmaceuticals shares are held by institutional investors. Comparatively, 0.4% of OptiBiotix Health shares are held by institutional investors. 65.1% of Celadon Pharmaceuticals shares are held by insiders. Comparatively, 26.8% of OptiBiotix Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

OptiBiotix Health has a net margin of -332.69% compared to Celadon Pharmaceuticals' net margin of -9,520.00%. OptiBiotix Health's return on equity of -77.85% beat Celadon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Celadon Pharmaceuticals-9,520.00% -131.82% -34.40%
OptiBiotix Health -332.69%-77.85%-13.93%

Summary

OptiBiotix Health beats Celadon Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does OptiBiotix Health compare to InnovaDerma?

InnovaDerma (LON:IDP) and OptiBiotix Health (LON:OPTI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

0.4% of OptiBiotix Health shares are owned by institutional investors. 26.8% of OptiBiotix Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, InnovaDerma's average media sentiment score of 0.00 equaled OptiBiotix Health'saverage media sentiment score.

Company Overall Sentiment
InnovaDerma Neutral
OptiBiotix Health Neutral

InnovaDerma has a net margin of 0.00% compared to OptiBiotix Health's net margin of -332.69%. InnovaDerma's return on equity of 0.00% beat OptiBiotix Health's return on equity.

Company Net Margins Return on Equity Return on Assets
InnovaDermaN/A N/A N/A
OptiBiotix Health -332.69%-77.85%-13.93%

InnovaDerma has higher revenue and earnings than OptiBiotix Health. OptiBiotix Health is trading at a lower price-to-earnings ratio than InnovaDerma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InnovaDerma£9.82M0.00N/A-£7.50N/A
OptiBiotix Health£1.29M4.73-£3.09M-£3.84N/A

Summary

InnovaDerma and OptiBiotix Health tied by winning 4 of the 8 factors compared between the two stocks.

Get OptiBiotix Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPTI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OPTI vs. The Competition

Export
MetricOptiBiotix HealthPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£6.02M£12.22B£7.11B£2.80B
Dividend YieldN/A2.63%2.53%6.18%
P/E Ratio-1.52797.14274.42366.17
Price / Sales4.67751.87600.7289,425.29
Price / Cash8.6881.7977.3827.89
Price / Book0.7510.4710.926.83
Net Income-£3.09M£2.83B£3.50B£5.89B
7 Day PerformanceN/A-1.64%-2.07%-0.75%
1 Month Performance4.02%-5.80%-6.32%16.84%
1 Year Performance-47.15%-3.84%8.92%16.40%

OptiBiotix Health Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OPTI
OptiBiotix Health
N/AGBX 5.83
-0.4%		N/A-50.4%£6.02M£1.29MN/A1
PXS
Provexis
N/AGBX 0.94
+4.6%		N/A+53.1%£22.08M£871.27KN/A4
MXC
Argent BioPharma
N/AN/AN/AN/A£9.65M£1.32MN/A5
RGT
Argent BioPharma
N/AN/AN/AN/A£8.31MN/AN/AN/A
CEL
Celadon Pharmaceuticals
N/AGBX 13.40
flat		N/AN/A£8.22M£123.38KN/A2,780

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:OPTI) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
A new kind of civil war is coming after election day?
Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...
Stansberry Research | Sponsoredtc pixel
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
My next big call (under $1)
Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...
Crypto 101 Media | Sponsoredtc pixel
Major Buy Alert Issued for October 31st
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel